Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria

NCT06350123 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06350123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06350123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2024
Completion date
May 9, 2025
Enrollment
324 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease